Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemothera

Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemothera

Item

http://www.wikidata.org/entity/Q33384675

Q33384675

about

Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity Evaluation of ultra-deep targeted sequencing for personalized breast cancer care.Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population.Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients.Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update.Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase.Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes.Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines.Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase gene

P2860

Q33576321-AB624C34-DB7E-423F-A973-2184BF1E5AEA Q33874148-8EDEDD19-0F0A-462C-85DA-43F8214F8F0D Q34008793-1FC58779-8E46-4C56-A426-C05471349B9D Q34134768-F409451E-F447-4028-AFC5-8BF9E60CEEEE Q34216563-ADB1D646-5F75-4A31-AF29-F849F72C898A Q35585759-7F2C2E46-466D-4038-8374-44E506011FCE Q36117656-5B8ADB98-8194-4A57-AD81-2EB54CE919DD Q37092485-22462931-B281-4A7A-B524-63E93AA6694E Q37290672-DC267646-2524-4B34-B4EA-8E9E3682E610 Q37690220-70076850-2008-4B26-A8B6-7D9E90820E69 Q38075827-C0B53A6E-092D-4DC2-A18E-47469807908B Q38127715-90F39006-9AA1-43D9-9C10-349E4189E46D Q39208906-48AEFD11-2F8E-447F-A3FA-FDCE37DA477F Q39566084-2F09E604-20DA-462E-98D0-4E8B47F76022 Q40546452-B0E35670-9AE9-41F9-9EDC-36C59D428640 Q42018846-7B55335D-F159-4CF2-9A05-ADA0B56139FD Q42210747-91F88BED-4FBC-42EE-8C70-DD2F83734913 Q42691338-FC00B530-4C31-41DC-A5BF-28E4BD124D92 Q47135784-B7A99409-E9B8-43C9-A3FB-15F050149678 Q50073098-2C3E6986-BEE0-40E3-8D04-4DDF3CF1E334 Q52591829-5BEA9789-5E85-4CE7-AD7C-BF3601AB162C Q55668963-0C2D7AC5-6115-4EDE-8B78-77B4F86D7CC6 Q57815793-D8A09AA7-42E8-4DDF-80FD-19B4DBFC2A91

P2860

Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemothera

Item

http://www.wikidata.org/entity/Q33384675

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu